A bacterium from frog gut microbiota eliminated tumors in mice by selectively colonizing tumors and triggering both direct ...

A total of 20 patients were included in the safety run-in cohort and completed preliminary evaluation. Results demonstrated that Opamtistomig in combination with chemotherapy was generally well ...

Affirma Biotech SL has disclosed new programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors potentially useful for the treatment of cancer, bacterial, fungal ...

Researchers at the Université de Genève have built a DNA-based drug delivery system that reads pairs of protein markers on a ...

Merck’s Keytruda plus paclitaxel ± bevacizumab gets EU approval to treat adults with PD-L1 platinum-resistant recurrent ovarian carcinoma who have received one or two prior systemic treatment regimens ...

The European approval is based on results from the Phase III KEYNOTE-B96 trial, which also supported the regimen's approval in the US.

The "Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers a comprehensive analysis of current and future ...

AZ has yet to file for approval of Imfinzi in the frontline setting for earlier-stage HCC, despite its well-established role ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in ...

A Rutgers Cancer Institute study in Cell Reports Medicine promises help with both those problems. It identifies a protein ...

Bicara Therapeutics is well-capitalized, with over $414.8M in cash and funding runway into H1 2029, but faces competitive ...

In A Nutshell A common blood pressure drug, telmisartan, boosted the effectiveness of a cancer drug in lab and mouse studies.